NewG Lab Pharma's Official YouTube Channel Surpasses 10,000 Subscribers in Just 2 Weeks

[Asia Economy Reporter Jang Hyowon] Recently, NewGene Lab Pharma's anticancer new drugs under development have been attracting significant attention from the industry due to remarkable achievements. Meanwhile, NewGene Lab Pharma's official corporate YouTube channel, which officially opened on the 12th, is showing a steep upward trend.

NewGene Lab Pharma, a company specializing in new drug development, announced on the 30th that its official YouTube channel surpassed 10,000 subscribers just two weeks after its launch. Since opening, the number of subscribers to NewGene Lab Pharma's YouTube channel has continuously increased, reaching 13,000 as of the 30th. The cumulative views have exceeded 60,000.

This upward trend is due to the recent progress of NewGene Lab Pharma's metabolic anticancer agent ‘KAT’ entering clinical trials in the US and Korea, followed by the domestic Phase 2 clinical trial of the non-small cell lung cancer treatment ‘Taletrectinib’ last month, which reaffirmed its excellent efficacy and was designated as an ‘FDA Breakthrough Therapy,’ making the achievements more visible.

Since opening, NewGene Lab Pharma has uploaded a total of three pieces of content on its YouTube channel, all featuring Executive Director Shin-Young Han, who explained in detail the mechanisms of KAT and Taletrectinib.

In the first content, the main topic was ‘Why metabolic anticancer agents are fundamental treatments.’ Executive Director Han stated, “While Merck’s representative immuno-oncology drug ‘Keytruda’ only responds in 10-20% of all patients, KAT responds to all patients. Moreover, it is a substance applicable to all cancers, and with an open clinical trial, rapid result confirmation after administration, and designation as an orphan drug, it can be sold immediately after completing Phase 2 clinical trials.”

The second content, which received the most attention, dealt in more detail with KAT’s mechanism of action, efficacy, clinical trials, and development plans. Executive Director Han said, “KAT selectively inhibits only the metabolic activity of cancer cells, killing only cancer cells. Preclinical experimental results and cases of complete cure of liver cancer through emergency clinical systems raise expectations for clinical success.”

The third content introduced the second pipeline, the lung cancer treatment ‘Taletrectinib.’ Executive Director Han introduced it as “A pipeline attracting attention with mid-term Phase 2 clinical results such as complete remission, blood-brain barrier (BBB) penetration effect, and high objective response rate (ORR). The market value of Taletrectinib is expected to exceed that of the US company ‘Turning Point,’ which recently sold a similar drug for over 5 trillion won.”

A NewGene Lab Pharma official said, “As visible results have begun to emerge from major pipelines recently, the company’s YouTube channel has started to receive much attention. We will continue to produce easy-to-understand content addressing questions and complex information for general investors and upload them regularly on the YouTube channel.”